Johnson and Johnson

Filed under: , , , , , , , , , , , , ,

It certainly is presumptuous, perhaps even self serving of me to assume the market is going higher in the face of so much uncertainty.

The reason I hold this belief is that so much money is sitting on the sidelines and much of it is getting restless. It’s one thing for those on a fixed income to suffer because the Federal Reserve is keeping interest rates so low, but it is quite another thing to expect $2 trillion dollars of corporate cash to want to live like senior citizens. That cash is a bigger drag on earnings with each passing day.

Then there is the competition between the deflation crowd investing in bonds and the inflation crowd investing in gold. You can be sure that both sides are doing their best to promote their view and one of them is going to be wrong — but it may take a few quarters.

Continue reading Chasing Value: Bonds, Gold, Stocks and Capital Flight

Chasing Value: Bonds, Gold, Stocks and Capital Flight originally appeared on BloggingStocks on Mon, 15 Nov 2010 16:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati


Filed under: , , , , , , ,

The market is down and the headlines are blaming Cisco Systems (CSCO), in part because they reported tepid earnings and somber growth projections. This once again underscores the fact that stock prices are always determined at the margins. Most folks could care less, and this is reflected by the big silent yawn of the majority of investors.

Cisco is not the bell-weather it has been in the past. Some of its business is down because there are more alternatives from competitors, “the cloud” keeps growing, and also many products have become commodities.

There are many other companies I would consider better measures of how the economy is doing.

Continue reading Chasing Value: Cisco Shmisco — It’s Nothing

Chasing Value: Cisco Shmisco — It’s Nothing originally appeared on BloggingStocks on Thu, 11 Nov 2010 14:30:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments

Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati


Filed under: ,

Johnson & Johnson (JNJ) has had its problems in recent times with recalls, but when you think about the stock, you can’t help thinking that it’s one of those blue-chip winners that will be around for a long time. It’s a name that you can utilize a dollar-cost-averaging strategy with in an attempt to keep the cost basis at an attractive level.

Today, the health-care concern issued its third-quarter report. While the top line failed to do much, as this article indicates, the bottom line was able to top the analyst community’s prediction. Net income came in at $1.23 per share, eight pennies ahead of the estimate. A weaker dollar did act as a partial driver of the profit performance.

Continue reading Johnson & Johnson Reports Q3 Numbers

Johnson & Johnson Reports Q3 Numbers originally appeared on BloggingStocks on Tue, 19 Oct 2010 17:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments

Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati


Filed under: , ,

Early Friday, American health care giant Johnson & Johnson (JNJ) announced that it is in “advanced talks” to acquire Dutch biotech firm Crucell NV. According to the report, the deal (which would help strengthen JNJ’s vaccine business) is going to cost $2.29 billion. JNJ already owns a 17.9% stake in Crucell and will be offering €24.75 in cash for the remaining 82%. The offer price represents a 58% premium from Crucell’s Thursday close.

In a joint statement, the companies noted expectations for “Crucell’s strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for Johnson & Johnson in the vaccine market.” According to the Associated Press, JNJ has roughly $64 billion in annual sales and is the “world’s biggest and most broadly based health care company.”

Continue reading Johnson & Johnson Sets Sites on Crucell: What Would This Mean for Stock?

Johnson & Johnson Sets Sites on Crucell: What Would This Mean for Stock? originally appeared on BloggingStocks on Fri, 17 Sep 2010 08:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati




Johnson & JohnsonCrucellBusinessUnited StatesHealth care